Yeomans Consulting Group Inc. Acquires New Holdings in Eli Lilly and Company (NYSE:LLY)

Yeomans Consulting Group Inc. purchased a new position in Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 876 shares of the company’s stock, valued at approximately $511,000.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $26,000. Tidemark LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at $29,000. Core Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the period. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the third quarter valued at $36,000. Finally, Frank Rimerman Advisors LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at $37,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the subject of a number of research reports. Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Argus boosted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $787.53.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 192,794 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $829.77, for a total transaction of $159,974,677.38. Following the completion of the sale, the insider now owns 98,208,810 shares in the company, valued at approximately $81,490,724,273.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Lilly Endowment Inc sold 192,794 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $829.77, for a total transaction of $159,974,677.38. Following the completion of the sale, the insider now owns 98,208,810 shares in the company, valued at approximately $81,490,724,273.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 567,826 shares of company stock worth $475,376,178. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.7 %

Shares of Eli Lilly and Company stock opened at $885.01 on Tuesday. The firm has a market capitalization of $841.12 billion, a PE ratio of 130.34, a P/E/G ratio of 1.92 and a beta of 0.36. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $892.20. The firm’s 50-day moving average price is $788.10 and its 200 day moving average price is $721.39. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period last year, the company posted $1.62 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a $1.30 dividend. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.59%. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.